ES2672526T3 - Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas - Google Patents

Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas Download PDF

Info

Publication number
ES2672526T3
ES2672526T3 ES09771199.8T ES09771199T ES2672526T3 ES 2672526 T3 ES2672526 T3 ES 2672526T3 ES 09771199 T ES09771199 T ES 09771199T ES 2672526 T3 ES2672526 T3 ES 2672526T3
Authority
ES
Spain
Prior art keywords
optionally substituted
drug
compound
formula
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09771199.8T
Other languages
English (en)
Spanish (es)
Inventor
Daniel V. Santi
Gary Ashley
Brian Hearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolynx LLC
Original Assignee
Prolynx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx LLC filed Critical Prolynx LLC
Application granted granted Critical
Publication of ES2672526T3 publication Critical patent/ES2672526T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES09771199.8T 2008-06-26 2009-06-26 Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas Active ES2672526T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13314808P 2008-06-26 2008-06-26
US133148P 2008-06-26
US19205008P 2008-09-15 2008-09-15
US192050P 2008-09-15
PCT/US2009/048943 WO2009158668A1 (en) 2008-06-26 2009-06-26 Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Publications (1)

Publication Number Publication Date
ES2672526T3 true ES2672526T3 (es) 2018-06-14

Family

ID=41444985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09771199.8T Active ES2672526T3 (es) 2008-06-26 2009-06-26 Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas

Country Status (7)

Country Link
US (2) US8680315B2 (enExample)
EP (1) EP2306986B1 (enExample)
JP (2) JP6084770B2 (enExample)
CN (1) CN102076331B (enExample)
DK (1) DK2306986T3 (enExample)
ES (1) ES2672526T3 (enExample)
WO (1) WO2009158668A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
US8703907B2 (en) * 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
BR112013031556B1 (pt) 2011-06-06 2022-03-29 Starpharma Pty Ltd Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas
JP6158185B2 (ja) * 2011-09-07 2017-07-05 プロリンクス エルエルシー 生分解性架橋を有するヒドロゲル
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
US20140256626A1 (en) * 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
JP6290187B2 (ja) * 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
SG11201603115YA (en) 2013-10-22 2016-05-30 Prolynx Llc Conjugates of somatostatin and its analogs
WO2015095755A1 (en) 2013-12-19 2015-06-25 Seattle Genetics, Inc. Methylene carbamate linkers for use with targeted-drug conjugates
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
AP2017009826A0 (en) 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
JP7017248B2 (ja) 2016-03-16 2022-02-08 プロリンクス エルエルシー エキセナチド類似体の持続放出コンジュゲート
CN106177977B (zh) * 2016-07-11 2020-09-04 天津科技大学 一种抗肿瘤药物三元偶联物及合成和应用
TWI773730B (zh) 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
EP3737383A4 (en) 2018-01-12 2021-12-15 Prolynx LLC SYNERGISTIC CANCER TREATMENT
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
CA3106568A1 (en) 2018-07-19 2020-01-23 Starpharma Pty Ltd Therapeutic dendrimer
JPWO2020050378A1 (ja) * 2018-09-06 2021-08-30 生化学工業株式会社 第３級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
WO2020067507A1 (ja) * 2018-09-28 2020-04-02 生化学工業株式会社 第１級アミン化合物又は第２級アミン化合物－酸性多糖コンジュゲートとその製造方法
CN114286693A (zh) 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
US20220265873A1 (en) 2019-08-07 2022-08-25 Prolynx Llc Steam sterilization of hydrogels crosslinked by beta-eliminative linkers
CN110423355B (zh) * 2019-08-29 2021-09-14 武汉轻工大学 羧甲基化莲藕多糖-曲古霉素a轭合物的制备方法
CN114630818A (zh) 2019-09-30 2022-06-14 北京轩义医药科技有限公司 蛋白-大分子偶联物及其使用方法
PH12022552719A1 (en) 2020-04-22 2024-02-05 Merck Sharp & Dohme Llc HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
WO2022214054A1 (en) * 2021-04-09 2022-10-13 Nanjing University Conjugate and the preparing method and use thereof
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE55594T1 (de) 1986-05-16 1990-09-15 Eka Nobel Ab Optisch aktives reagens und verfahren zur determinierung von enantiomeren aminverbindungen.
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
WO1998004534A1 (en) * 1996-07-31 1998-02-05 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and medicinal compositions containing the same
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
JPH11130711A (ja) * 1997-10-24 1999-05-18 Teijin Ltd １α，２４，２５−トリヒドロキシビタミンＤ３類の合成中間体およびその製造法
WO2000029386A1 (en) * 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6114566A (en) * 1999-05-24 2000-09-05 Board Of Trustees Operating Michigan State University 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof
EP1210093A4 (en) * 1999-09-03 2005-01-12 Polytherics Ltd DEGRADABLE POLYMERS
US6861162B2 (en) 2002-08-28 2005-03-01 Cityu Research Ltd. Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
CA2521784C (en) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2004089279A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
JP2006067889A (ja) 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
EP1853294A4 (en) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
CN101287835A (zh) 2005-08-17 2008-10-15 株式会社百奥尼 用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
JP5224016B2 (ja) * 2006-03-10 2013-07-03 晃二 有光 感活性エネルギー線塩基発生剤、感活性エネルギー線塩基発生剤組成物、塩基反応性組成物及びパターン形成方法
US20100168443A1 (en) 2006-11-02 2010-07-01 University Of Virginia Patent Foundation Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
HUE054585T2 (hu) * 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek

Also Published As

Publication number Publication date
CN102076331B (zh) 2013-12-18
CN102076331A (zh) 2011-05-25
US20140296476A1 (en) 2014-10-02
WO2009158668A1 (en) 2009-12-30
JP6084770B2 (ja) 2017-02-22
EP2306986B1 (en) 2018-03-21
DK2306986T3 (en) 2018-06-18
EP2306986A4 (en) 2015-01-28
JP2011528654A (ja) 2011-11-24
EP2306986A1 (en) 2011-04-13
US9387254B2 (en) 2016-07-12
US8680315B2 (en) 2014-03-25
JP2015172078A (ja) 2015-10-01
US20110263502A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
Rahimizadeh et al. Albumin: an emerging opportunity in drug delivery
ES2390816T3 (es) N,N-bis-(2-hidroxietil) glicina amida como ligador en profármacos conjugados con polímeros
JP7512207B2 (ja) 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
ES2741524T3 (es) Profármaco polimérico con un enlazador autoinmolador
ES2791683T3 (es) Sistemas a base de conjugados para la administración controlada de fármacos
DK2306986T3 (en) PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
JP4474521B2 (ja) チオエステル末端化水溶性ポリマーおよびそれを用いてポリペプチドのｎ末端を改変する方法
US10111963B2 (en) Nanoparticle drug conjugates
US20110294189A1 (en) Biomolecule polymer conjugates and methods for making the same
WO2014081301A1 (en) Bio-orthogonal drug activation
JP2013541510A (ja) 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
CA3041950C (en) DELIVERY SYSTEM DESIGNED FOR THE TARGET DELIVERY OF A THERAPEUTICALLOUS PAYLOAD
IL267806B2 (en) Multimeric oligonucleotides having decreased kidney clearance
JP6814824B2 (ja) アポトーシスを誘導するための組成物及び方法
CN114392358A (zh) 一种肿瘤靶向的核酸适体药物偶连物
Pasut et al. A new PEG− β-alanine active derivative for releasable protein conjugation
CN102441175A (zh) 人血清白蛋白-siRNA纳米尺寸载体系统
JP2023501020A (ja) 治療用分子の標的化送達
KR20130022671A (ko) 전립선암 특이적 ｓｉＲＮＡ 전달체
Kwon et al. Site-Selective Anti-PD-L1 Antibody–MMAE Conjugate for Enhanced NSCLC Therapy
US20250049927A1 (en) Modified oligonucleotide-drug conjugate and use thereof
Ochtrop et al. Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates
An et al. Bioreducible crosslinked cationic nanopolyplexes from clickable polyethylenimines enabling robust cancer gene therapy
JP2023546558A (ja) アミド結合を含むリンカー化合物
ES2875459T3 (es) Complejos nanoensamblados de ácidos nucleicos, avidina y compuestos biotinilados para el uso como portadores de fármacos